treatment of minimal residual disease in aml patients
Published 8 years ago • 742 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
3:35
minimal residual disease (mrd) as a prognostic factor for acute myeloid leukemia (aml)
-
1:49
the prognostic value of flt3-itd residual disease in aml
-
5:12
an insight into myelomatch: enabling rapid advancements in the treatment of myeloid malignancies
-
2:09
advances in the management of fit adults with aml
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:19
new treatments for aml
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
3:06
what happens in treatment failure in aml?
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
1:46
how would the approval of luspatercept benefit the treatment landscape in myelofibrosis
-
0:37
the mechanism of treatment resistance in aml: do cd8-expressing t-cells become exhausted?
-
0:52
a real-world study of the optimal duration of cpx-351 treatment in patients with aml
-
2:34
the evolution of the aml treatment paradigm
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
2:13
haploidentical sct for the treatment of secondary aml
-
1:20
flt3 inhibitors as mrd-guided salvage treatment for molecular failure in flt3-mutated aml
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
1:28
cd47 antibodies for the treatment of aml and mds: where is the field moving?
-
4:30
measurable residual disease in aml
-
10:40
genomic residual disease in aml prior to allo-sct: fate or early intervention opportunity?
-
1:44
improving maintenance therapy in aml: exploring the role of idh inhibitors